Pacific View Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Pacific View Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-58,902	Closed	-$1.42M	–	50
2019 Q2	$1.42M	Sell	58,902 -17,546	-23%	-$445K	1.54%	19
2019 Q1	$2.02M	Buy	76,448 +42,452	+125%	+$1.01M	2.1%	14
2018 Q4	$664K	Buy	+33,996	New	+$666K	0.78%	28

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacific View Asset Management's HZNP Position: Q3 2019 in Review

Pacific View Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2019, closing a stake of 58,902 shares — an estimated $1.42M sold.

Pacific View Asset Management first reported a position in HZNP in Q4 2018 and held it in 3 quarters. The position peaked at $2.02M in Q1 2019. 264 funds tracked by Wall St. Rank hold HZNP as of Q3 2019.

Pacific View Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2019 after selling out during the quarter.
Pacific View Asset Management sold 58,902 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2019, an estimated $1.42M.
Pacific View Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2018 and held it in 3 quarters.
Pacific View Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.02M in Q1 2019.
264 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2019.

Based on Pacific View Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.